Evidence Trace, complete trial record
In plain terms
In plain terms: Infrared Sauna shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Infrared Sauna
C
Limited: small, mixed or unreplicated trials
The endpoint this grade is based on: Surrogate biomarker endpoint
The evidence as the record states it
Tei et al. (Circulation Journal, 2016; PMID 27001189, Waon therapy), Masuda et al. (Japanese Heart Journal, 2004; PMID 15090706), Hussain et al. (Complementary Therapies in Medicine, 2022; PMID 34954348) and Schenaarts et al. (2024; PMID 39209309): randomized trials of sauna/Waon therapy. Grade C: one heart failure trial whose primary endpoint was null, and marker trials that are small and mixed.
PMID 27001189 PMID 15090706 PMID 34954348 PMID 39209309
Evidence by specific use
Chronic heart failure (adjunct)
Grade C
Tei et al. (Circ J, 2016; PMID 27001189), WAON-CHF: 149 hospitalized patients with advanced heart failure, 10 days of Waon therapy or control. The primary endpoint, B-type natriuretic peptide, did not differ significantly; NYHA class, six-minute walk distance and cardiothoracic ratio improved. One trial, its primary endpoint null, not repeated by an independent group: C.
PMID 27001189
Vascular / oxidative-stress markers
Grade C
Masuda et al. (Jpn Heart J, 2004; PMID 15090706): 28 patients with coronary risk factors, 2 weeks; a urinary oxidative-stress marker and systolic pressure fell. Hussain et al. (Complement Ther Med, 2022; PMID 34954348): a single-session crossover in 10 women, no change in blood pressure or arterial stiffness. An oxidative-stress marker is not an established stand-in for a clinical outcome, and the evidence is one small positive trial against a null one: C.
PMID 15090706 PMID 34954348
Acute glycemic control, T2DM
Grade D
PMID 39209309
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What this grade covers and what it does not
Grade C. The heart failure use rests on one multicenter trial, WAON-CHF (Tei et al., Circ J, 2016; PMID 27001189), whose primary endpoint, B-type natriuretic peptide, did not differ; functional class and walk distance improved as secondary outcomes. The vascular use rests on a 28-person, 2-week trial on a urinary oxidative-stress marker (Masuda et al., 2004; PMID 15090706) against a null single-session crossover (Hussain et al., 2022; PMID 34954348). Neither meets the B definition. WHAT THIS GRADE DOES NOT COVER: mortality, where the Finnish sauna data are observational and carry no letter.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.
How to track whether this is working
Resting heart rate and blood pressure at baseline and every 4 weeks. Session frequency, temperature, and duration to confirm the protocol matches studied parameters (4+ sessions/week, 174-212F, 20 minutes). If using for recovery, track DOMS scores and performance recovery time across training blocks.